Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 10:00 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: FMD Clear all
Terminated Phase 2 Interventional Results available

Extension Study to Evaluate the Long-Term Effects of ACE-083 in Patients With Facioscapulohumeral Muscular Dystrophy (FSHD) and Charcot-Marie Tooth (CMT) Disease Types 1 and X (CMT1 and CMTX)

NCT03943290
View directory record Official record
Conditions
Facioscapulohumeral Muscular Dystrophy, Charcot-Marie-Tooth Disease
Interventions
ACE-083
Drug
Lead sponsor
Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA
Industry
Eligibility
18 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
19
States / cities
Orange, California • Sacramento, California • Aurora, Colorado + 16 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2022 · Synced Jul 22, 2026, 10:00 AM EDT
Recruiting No phase listed Observational

Survey on Physical Activity and Qualify of Life in Fibromuscular Dysplasia

NCT07529691
View directory record Official record
Conditions
Fibromuscular Dysplasia of Arteries, Fibromuscular Dysplasia, Spontaneous Coronary Artery Dissection
Interventions
Not listed
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years to 100 Years
Enrollment
2,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 19, 2026 · Synced Jul 22, 2026, 10:00 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Safety, Tolerability, Pharmacokinetics, and Biological Activity of ATYR1940 in Adult Participants With Muscular Dystrophy

NCT02239224
View directory record Official record
Conditions
Facioscapulohumeral Muscular Dystrophy (FSHD)
Interventions
Placebo, ATYR1940
Biological
Lead sponsor
aTyr Pharma, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
2
States / cities
Rochester, New York • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 10, 2021 · Synced Jul 22, 2026, 10:00 AM EDT
Recruiting Not applicable Interventional

Fasting During Neoadjuvant Chemotherapy in Patient With Epithelial Ovarian Cancer

NCT06386887
View directory record Official record
Conditions
Epithelial Ovarian Cancer
Interventions
Intermittent Fasting, Neoadjuvant chemotherapy
Behavioral · Drug
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 24, 2026 · Synced Jul 22, 2026, 10:00 AM EDT
Recruiting No phase listed Observational

BetterLife FSHD: A Patient-driven Health and Research Platform

NCT07409142
View directory record Official record
Conditions
FSH, FSH Muscular Dystrophy, FSHD - Facioscapulohumeral Muscular Dystrophy, FSHD1, FSHD, FSHD2, Facioscapulohumeral Muscular Dystrophy, Facioscapulohumeral Muscular Dystrophy 1, Facioscapulohumeral Muscular Dystrophy 2, Facioscapulohumeral Muscular Dystrophy (FSHD), Muscular Dystrophy, Facioscapulohumeral
Interventions
Observational
Other
Lead sponsor
FSHD Society
Other
Eligibility
1 Year and older
Enrollment
5,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2060
U.S. locations
1
States / cities
Randolph, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 19, 2026 · Synced Jul 22, 2026, 10:00 AM EDT
Terminated No phase listed Observational

FSHD Molecular Characterization

NCT06096441
View directory record Official record
Conditions
Facio-Scapulo-Humeral Dystrophy
Interventions
Not listed
Lead sponsor
Nationwide Children's Hospital
Other
Eligibility
13 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 17, 2025 · Synced Jul 22, 2026, 10:00 AM EDT
Terminated Phase 2 Interventional Results available

Efficacy and Safety of Losmapimod in Treating Subjects With Facioscapulohumeral Muscular Dystrophy (FSHD) With Open-Label Extension (OLE)

NCT04264442
View directory record Official record
Conditions
Facioscapulohumeral Muscular Dystrophy (FSHD)
Interventions
Losmapimod
Drug
Lead sponsor
Fulcrum Therapeutics
Industry
Eligibility
18 Years to 65 Years
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
12
States / cities
Irvine, California • Los Angeles, California • Gainesville, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Sep 29, 2025 · Synced Jul 22, 2026, 10:00 AM EDT
Completed Not applicable Interventional

Study: Effects of Strawberries on Blood Pressure

NCT01190319
View directory record Official record
Conditions
Pre-hypertension
Interventions
Strawberry Beverage, Placebo
Other
Lead sponsor
University of California, Davis
Other
Eligibility
25 Years to 65 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2015
U.S. locations
1
States / cities
Davis, California
Source: ClinicalTrials.gov public record
Updated Jul 12, 2017 · Synced Jul 22, 2026, 10:00 AM EDT
Active, not recruiting Phase 2 Interventional

Phase 2 Open-label Extension Study of AOC 1020 in Participants With Facioscapulohumeral Muscular Dystrophy (FSHD)

NCT06547216
View directory record Official record
Conditions
FSHD, FSHD1, FSHD2, FMD, FMD2, Fascioscapulohumeral Muscular Dystrophy, Fascioscapulohumeral Muscular Dystrophy Type 1, Fascioscapulohumeral Muscular Dystrophy Type 2, Dystrophies, Facioscapulohumeral Muscular, Dystrophy, Facioscapulohumeral Muscular, Facioscapulohumeral Muscular Dystrophy 1, Facioscapulohumeral Muscular Dystrophy 2, Facio-Scapulo-Humeral Dystrophy, Atrophy, Facioscapulohumeral, Atrophies, Facioscapulohumeral, Facioscapulohumeral Atrophy, Muscular Dystrophies, Muscular Dystrophy, Facioscapulohumeral, FSH Muscular Dystrophy, Landouzy Dejerine Dystrophy, Landouzy-Dejerine Muscular Dystrophy, Dystrophies, Landouzy-Dejerine, Dystrophy, Landouzy-Dejerine, Landouzy-Dejerine Syndrome, Muscular Dystrophy, Landouzy Dejerine, Progressive Muscular Dystrophy, FSH
Interventions
AOC 1020
Drug
Lead sponsor
Avidity Biosciences, Inc.
Industry
Eligibility
16 Years to 72 Years
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
14
States / cities
Los Angeles, California • Palo Alto, California • San Diego, California + 11 more
Source: ClinicalTrials.gov public record
Updated Jul 13, 2026 · Synced Jul 22, 2026, 10:00 AM EDT
Recruiting Phase 1 Interventional

Safety and Preliminary Efficacy of ULSC in Facioscapulohumeral Muscular Dystrophy (FSHD)

NCT07086521
View directory record Official record
Conditions
FSHD - Facioscapulohumeral Muscular Dystrophy
Interventions
ULSC, Placebo
Biological
Lead sponsor
Restem, LLC.
Industry
Eligibility
15 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Dec 7, 2025 · Synced Jul 22, 2026, 10:00 AM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety of Losmapimod in Subjects With Facioscapulohumeral Muscular Dystrophy (FSHD)

NCT04003974
View directory record Official record
Conditions
Facioscapulohumeral Muscular Dystrophy (FSHD)
Interventions
Losmapimod oral tablet, Placebo oral tablet
Drug
Lead sponsor
Fulcrum Therapeutics
Industry
Eligibility
18 Years to 65 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
12
States / cities
Irvine, California • Los Angeles, California • Gainesville, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Jul 9, 2024 · Synced Jul 22, 2026, 10:00 AM EDT
Recruiting Phase 1 Interventional

Botensilimab Plus Balstilimab and Fasting Mimicking Diet Plus Vitamin C for Patients With KRAS-Mutant Metastatic Colorectal Cancer

NCT06336902
View directory record Official record
Conditions
Metastatic Colorectal Adenocarcinoma, Stage IV Colorectal Cancer AJCC v8
Interventions
Balstilimab, Biospecimen Collection, Botensilimab, Computed Tomography, Dietary Intervention, Magnetic Resonance Imaging, Vitamin C
Biological · Procedure · Other + 1 more
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
3
States / cities
Fullerton, California • Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 16, 2026 · Synced Jul 22, 2026, 10:00 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Myotonic Dystrophy and Facioscapulohumeral Muscular Dystrophy Registry

NCT00082108
View directory record Official record
Conditions
Myotonic Dystrophy, Facioscapulohumeral Muscular Dystrophy, Muscular Dystrophy, Myotonic Dystrophy Type 1, Myotonic Dystrophy Type 2, Congenital Myotonic Dystrophy, PROMM (Proximal Myotonic Myopathy), Steinert's Disease, Myotonic Muscular Dystrophy
Interventions
Not listed
Lead sponsor
University of Rochester
Other
Eligibility
Not listed
Enrollment
3,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2000 – 2028
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Oct 14, 2025 · Synced Jul 22, 2026, 10:00 AM EDT
Completed Phase 1 Interventional Results available

Study of Testosterone and rHGH in FSHD

NCT03123913
View directory record Official record
Conditions
Facioscapulohumeral Muscular Dystrophy
Interventions
Testosterone Enanthate, Somatropin
Drug
Lead sponsor
University of Rochester
Other
Eligibility
18 Years to 65 Years · Male only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated May 15, 2023 · Synced Jul 22, 2026, 10:00 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Probing the Role of Mitochondrial Oxidative Stress in Impaired Vascular Function Among Young Adults With Early Life Adversity

NCT07244809
View directory record Official record
Conditions
Adverse Childhood Experience, Endothelial Function (FMD), Endothelial Injury, Mitochondrial Function, Oxidative Stress, Psychosocial Influence on Cardiovascular Disease
Interventions
Mitoquinone mesylate (MitoQ), Placebo
Dietary Supplement
Lead sponsor
University of Iowa
Other
Eligibility
18 Years to 29 Years
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Nov 23, 2025 · Synced Jul 22, 2026, 10:00 AM EDT
Not yet recruiting Not applicable Interventional

A Nutritional Intervention for Body, Brain, and Longevity Effects (NIBBLE)

NCT06682767
View directory record Official record
Conditions
Cerebral Blood Flow, APOE 4
Interventions
FMD1 (LNT22-017-1), Dietary Guidance
Dietary Supplement · Behavioral
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
45 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Feb 8, 2026 · Synced Jul 22, 2026, 10:00 AM EDT
Completed No phase listed Observational

Clinical Correlates of COVID-19 Pandemic in Patients With Functional Movement Disorder (FMD) and Parkinson's Disease (PD)

NCT04565080
View directory record Official record
Conditions
Parkinson's Disease, Functional Movement Disorders, COVID-19
Interventions
Not listed
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 21, 2021 · Synced Jul 22, 2026, 10:00 AM EDT
Completed Not applicable Interventional

Effects of an Intermittent Reduced Calorie Diet on Crohn's Disease

NCT04147585
View directory record Official record
Conditions
Inflammatory Bowel Diseases, Crohn Disease, Diet Modification
Interventions
Intermittent Reduced Calorie Diet (IRCD)
Other
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 70 Years
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Apr 16, 2025 · Synced Jul 22, 2026, 10:00 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Evaluate Safety and Biological Activity of ATYR1940 in Participants With Limb Girdle Muscular Dystrophy 2B (LGMD2B) and Facioscapulohumeral Muscular Dystrophy (FSHD)

NCT02579239
View directory record Official record
Conditions
Limb-Girdle Muscular Dystrophies, Facioscapulohumeral Muscular Dystrophy
Interventions
ATYR1940, Placebo
Biological
Lead sponsor
aTyr Pharma, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
3
States / cities
Irvine, California • Baltimore, Maryland • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 18, 2023 · Synced Jul 22, 2026, 10:00 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Biomarker Development for Muscular Dystrophies

NCT05019625
View directory record Official record
Conditions
Myotonic Dystrophy, Duchenne Muscular Dystrophy, Becker Muscular Dystrophy, Facioscapulohumeral Muscular Dystrophy
Interventions
Not listed
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
5 Years and older
Enrollment
465 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2028
U.S. locations
5
States / cities
Boston, Massachusetts • Winston-Salem, North Carolina • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 23, 2025 · Synced Jul 22, 2026, 10:00 AM EDT
Completed No phase listed Observational

Study of the Ability of a New Technique to Effectively Diagnose Movement Disorders

NCT03661021
View directory record Official record
Conditions
Functional Movement Disorder
Interventions
Not listed
Lead sponsor
The Cleveland Clinic
Other
Eligibility
Not listed
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 12, 2025 · Synced Jul 22, 2026, 10:00 AM EDT
Terminated Phase 3 Interventional Results available

Efficacy and Safety of Losmapimod in Treating Participants With Facioscapulohumeral Muscular Dystrophy (FSHD) (REACH)

NCT05397470
View directory record Official record
Conditions
Facioscapulohumeral Muscular Dystrophy (FSHD)
Interventions
Losmapimod, Placebo oral tablet
Drug
Lead sponsor
Fulcrum Therapeutics
Industry
Eligibility
18 Years to 65 Years
Enrollment
260 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
14
States / cities
Irvine, California • Los Angeles, California • Aurora, Colorado + 11 more
Source: ClinicalTrials.gov public record
Updated Nov 9, 2025 · Synced Jul 22, 2026, 10:00 AM EDT
Not listed No phase listed Observational

Validation of Optical Genome Mapping for the Identification of Constitutional Genomic Variants in a Postnatal Cohort

NCT05295277
View directory record Official record
Conditions
Developmental Disability, Intellectual Disability, Autism Spectrum Disorder, Congenital Anomaly, Fragile X Syndrome, Facioscapulohumeral Muscular Dystrophy 1
Interventions
Standard of care genetic testing group
Other
Lead sponsor
Bionano Genomics
Industry
Eligibility
Not listed
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
8
States / cities
Atlanta, Georgia • Augusta, Georgia • Iowa City, Iowa + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 6, 2023 · Synced Jul 22, 2026, 10:00 AM EDT
Completed Not applicable Interventional Results available

Phosphodiesterase Type 5 Inhibition to Improve Endothelial Function and Vascular Remodeling in Chronic Kidney Disease and End Stage Renal Disease Patients Requiring New Arteriovenous Fistula

NCT02414204
View directory record Official record
Conditions
Improve Endothelial Function and Decrease Vascular Stenosis
Interventions
Sildenafil, Placebo
Drug · Other
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
19 Years to 99 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Aug 11, 2019 · Synced Jul 22, 2026, 10:00 AM EDT